Population pharmacokinetics

Population pharmacokinetics of omeprazole in a random Iranian population

Background: Omeprazole is metabolized predominantly by CYP2C19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. These variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. The aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random Iranian population. Met...

Pharmacokinetics in pediatric population

Population Pharmacokinetics -- final

Population pharmacokinetics of exenatide

AIM The aim of the present analysis was to develop a core population pharmacokinetic model for the pharmacokinetic properties of immediate-release (IR) exenatide, which can be used in subsequent analyses of novel sustained-release formulations. METHODS Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis. All modell...

Population Pharmacokinetics of Pomalidomide

A population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demographic and disease-related covariates on PPK parameters was assessed based on data from 6 clinical trials of pomalidomide (dose range, 0.5-10 mg) in healthy participants (n = 96) and patients with multiple myeloma (MM; n = 144). PPK data described herein suggest that systemic clearance of pomalidomi...